ArticlePakistan journal of medical sciences2026
Is p53 Immunohistochemistry a Reliable Indicator of
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the concordance between p53 immunohistochemistry (IHC) patterns and Methodology: In this retrospective study, 166 lung adenocarcinoma cases diagnosed between 2020 and 2025 at the Department of Medical Pathology, Karadeniz Technical University Faculty of Medicine were analyzed. p53 IHC staining was classified as overexpression, null, or wild-type. Results: p53 IHC showed overexpression in one hundred eighteen cases (71.1%), a null pattern in forty-two (25.3%), and wild-type staining in six (3.6%). Conclusions: p53 IHC is a reliable surrogate marker for identifying TP53 missense mutations in lung adenocarcinoma, with overexpression demonstrating excellent diagnostic accuracy. Although the null pattern has limited PPV for nonsense mutations, its high NPV supports its use in excluding such variants. p53 IHC may serve as a practical and cost-effective approach for inferring TP53 mutation status, particularly in settings where molecular testing is restricted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.